Full text is available at the source.
Abstract
Semaglutide is associated with reduced risk of adverse cardiovascular outcomes in non-diabetic individuals with obesity and pre-existing cardiovascular disease.
- The use of semaglutide may lower the likelihood of cardiovascular issues.
- This effect is observed specifically in non-diabetic patients.
- Individuals with obesity and existing cardiovascular conditions may benefit from treatment with semaglutide.
Simplified